These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 26348208)
41. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537 [TBL] [Abstract][Full Text] [Related]
42. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611 [TBL] [Abstract][Full Text] [Related]
43. A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations. Crum MF; Trevaskis NL; Williams HD; Pouton CW; Porter CJ Pharm Res; 2016 Apr; 33(4):970-82. PubMed ID: 26703975 [TBL] [Abstract][Full Text] [Related]
44. Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles. Jin X; Huang A; Ping Q; Cao F; Su Z Pharmazie; 2011 May; 66(5):339-47. PubMed ID: 21699067 [TBL] [Abstract][Full Text] [Related]
45. Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate. Hugo M; Kunath K; Dressman J Drug Dev Ind Pharm; 2013 Feb; 39(2):402-12. PubMed ID: 22591213 [TBL] [Abstract][Full Text] [Related]
46. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium. Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899 [TBL] [Abstract][Full Text] [Related]
47. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. Radwant MA; Aboul-Enein HY J Microencapsul; 2002; 19(2):225-35. PubMed ID: 11837977 [TBL] [Abstract][Full Text] [Related]
48. Silk sericin loaded alginate nanoparticles: Preparation and anti-inflammatory efficacy. Khampieng T; Aramwit P; Supaphol P Int J Biol Macromol; 2015 Sep; 80():636-43. PubMed ID: 26188300 [TBL] [Abstract][Full Text] [Related]
49. Sericin reduces serum cholesterol in rats and cholesterol uptake into Caco-2 cells. Limpeanchob N; Trisat K; Duangjai A; Tiyaboonchai W; Pongcharoen S; Sutheerawattananonda M J Agric Food Chem; 2010 Dec; 58(23):12519-22. PubMed ID: 21058738 [TBL] [Abstract][Full Text] [Related]
50. Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared from water-in-oil microemulsions by copolymerization. Liang M; Davies NM; Toth I Int J Pharm; 2008 Oct; 362(1-2):141-6. PubMed ID: 18598746 [TBL] [Abstract][Full Text] [Related]
51. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Granero GE; Ramachandran C; Amidon GL Drug Dev Ind Pharm; 2005 Oct; 31(9):917-22. PubMed ID: 16306004 [TBL] [Abstract][Full Text] [Related]
52. [Property studies on three-dimensional porous blended silk scaffolds]. Rao J; Shen J; Quan D; Xu Y Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Oct; 23(10):1264-70. PubMed ID: 19957853 [TBL] [Abstract][Full Text] [Related]
53. Manufacturing nanosized fenofibrate by salt assisted milling. Mochalin VN; Sagar A; Gour S; Gogotsi Y Pharm Res; 2009 Jun; 26(6):1365-70. PubMed ID: 19224343 [TBL] [Abstract][Full Text] [Related]
54. The characterization of protein release from sericin film in the presence of an enzyme: towards fibroblast growth factor-2 delivery. Nishida A; Naganuma T; Kanazawa T; Takashima Y; Yamada M; Okada H Int J Pharm; 2011 Jul; 414(1-2):193-202. PubMed ID: 21619916 [TBL] [Abstract][Full Text] [Related]
55. The stability and controlled release of I-ascorbic acid encapsulated in poly (ethyl-2-cyanoacrylate) nanocapsules prepared by interfacial polymerization of water-in-oil microemulsions. Zhang SN; Chen T; Guo YG; Zhang J; Song X; Zhou L J Cosmet Sci; 2015; 66(4):247-59. PubMed ID: 26665980 [TBL] [Abstract][Full Text] [Related]
56. IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods. Buch P; Holm P; Thomassen JQ; Scherer D; Kataoka M; Yamashita S; Langguth P Pharmazie; 2011 Jan; 66(1):11-6. PubMed ID: 21391429 [TBL] [Abstract][Full Text] [Related]
57. The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat. Kaur J; Reddy K; Balakumar P Cardiovasc Toxicol; 2010 Sep; 10(3):227-38. PubMed ID: 20694523 [TBL] [Abstract][Full Text] [Related]
58. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Kon Koh K; Yeal Ahn J; Hwan Han S; Kyu Jin D; Sik Kim H; Cheon Lee K; Kyun Shin E; Sakuma I Atherosclerosis; 2004 Jun; 174(2):379-83. PubMed ID: 15136070 [TBL] [Abstract][Full Text] [Related]
59. Novel genipin crosslinked atorvastatin loaded sericin nanoparticles for their enhanced antihyperlipidemic activity. Kanoujia J; Singh M; Singh P; Saraf SA Mater Sci Eng C Mater Biol Appl; 2016 Dec; 69():967-76. PubMed ID: 27612792 [TBL] [Abstract][Full Text] [Related]
60. Sulfated sericin is a novel anticoagulant influencing the blood coagulation cascade. Sano M; Tamada Y; Niwa K; Morita T; Yoshino G J Biomater Sci Polym Ed; 2009; 20(5-6):773-83. PubMed ID: 19323889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]